new IV antibiotic for methicillin-resistant Staph aureus (MRSA) infections, Vibativ (vy-BA-tiv)

Please see the June 2013 FDA release regarding the expanded use of Vibativ

You'll soon see a new IV antibiotic for methicillin-resistant Staph aureus (MRSA) infections, Vibativ (vy-BA-tiv).

It's the first in a new class. But it's related to vancomycin...and has many of vanco's drawbacks.

Vibativ (telavancin) is only approved for complicated skin and skin structure infections in adults. It covers gram-positive bacteria, including MRSA.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote